BIOTICA ENTERS INTO A RESEARCH AND LICENSE AGREEMENT WITH WYETH FOR NOVEL RAPAMYCIN ANALOGS

Biotica Technology Ltd. a private UK biotechnology company, announced the signing of an exclusive research collaboration and license agreement with Wyeth Pharmaceuticals, a division of Wyeth. This alliance is focused on the discovery, development and commercialization of novel rapamycin analogs that target diseases in multiple therapeutic areas. Biotica (http://www.biotica.co.uk/4oct2006.htm)